Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
EuroIntervention. 2019 Jul 20;15(4):e354-e361. doi: 10.4244/EIJ-D-18-00538.
We aimed to evaluate the contribution of the retrograde approach to real-world practice over time and its long-term outcomes in chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
We evaluated 1,635 CTO procedures conducted at our high-volume centre between 2003 and 2015. The retrograde approach has been actively adopted in practice since January 2007. The primary endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularisation/reocclusion. The technical success rate of CTO-PCI has increased from 79.5% to 87.1% since 2007, although the complexity of the CTOs has also significantly increased in that time (J-CTO scores: from 1.8±1.2 to 2.0±1.1, p=0.03). The incidence of in-hospital MACCE using the retrograde approach was 4.5%, which was comparable to the antegrade-only approach rate of 4.1% (p=0.58). The retrograde approach showed a higher four-year TVF rate after successful stenting compared with the antegrade-only approach (17.1% vs 9.4%, p=0.01), but this difference was mainly driven by a higher target vessel revascularisation/reocclusion rate. Multivariable analysis revealed that renal dysfunction (hazard ratio [HR] 3.33, 95% confidence interval [CI]: 1.42-7.83), acute coronary syndrome (HR 1.99, 95% CI: 1.26-3.14), the J-CTO score (per 1, HR 1.23, 95% CI: 1.00-1.51), and the smallest stent diameter (per 1 mm, HR 0.39, 95% CI: 0.21-0.74) (all p<0.05) were independently associated with TVF.
A retrograde approach contributes to the increased success of more complex CTO-PCI over time with an acceptable frequency of in-hospital complications and four-year TVF rate.
本研究旨在评估逆行介入技术在真实世界中的应用随时间推移的贡献,并评估其在慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)中的长期结果。
我们评估了 2003 年至 2015 年间在我们高容量中心进行的 1635 例 CTO 手术。逆行介入技术自 2007 年 1 月以来已在实践中积极采用。主要终点是靶血管失败(TVF),包括心源性死亡、靶血管相关心肌梗死或靶血管血运重建/再闭塞。自 2007 年以来,CTO-PCI 的技术成功率已从 79.5%提高到 87.1%,尽管在此期间 CTO 的复杂性也显著增加(J-CTO 评分:从 1.8±1.2 增加到 2.0±1.1,p=0.03)。使用逆行介入技术的住院期间 MACCE 的发生率为 4.5%,与单纯顺行介入技术的发生率(4.1%)相当(p=0.58)。与单纯顺行介入技术相比,逆行介入技术在成功支架置入后的四年 TVF 率更高(17.1%比 9.4%,p=0.01),但这种差异主要是由于靶血管血运重建/再闭塞率较高所致。多变量分析显示,肾功能不全(危险比[HR]3.33,95%置信区间[CI]:1.42-7.83)、急性冠状动脉综合征(HR 1.99,95%CI:1.26-3.14)、J-CTO 评分(每增加 1 分,HR 1.23,95%CI:1.00-1.51)和最小支架直径(每增加 1 毫米,HR 0.39,95%CI:0.21-0.74)(均 p<0.05)与 TVF 独立相关。
逆行介入技术随着时间的推移,在越来越复杂的 CTO-PCI 中取得了更高的成功率,同时具有可接受的住院并发症发生率和四年 TVF 率。